临床试验/NCT06717126

NCT06717126进行中（未招募）2 期

A Phase II, Multi-centre, Open Label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients With Advanced/Metastatic Ocular/Uveal Melanoma

iOnctura16 个研究点分布在 3 个国家目标入组 85 人开始时间: 2025年2月27日最近更新: 2026年1月16日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方
入组人数: 85
试验地点: 16
主要终点: Overall survival

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are:

Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?

详细描述

A Phase II open-label, randomised, parallel-arm study, which will assess the clinical efficacy of oral roginolisib (IOA 244 [roginolisib hemi-fumarate]) as monotherapy against a control of Investigator´s treatment choice in patients with advanced or metastatic uveal melanoma (UM).

This study will enrol approximately 85 male and female patients aged over 18 years with advanced or metastatic UM, who have progressed following at least 1 prior immunotherapy treatment. The disease must be measurable (i.e., at least 1 measurable lesion) as per RECIST v1.1 by Computerised Tomography (CT) scan or Magnetic Resonance Imaging (MRI).

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female aged 18 years or older;
•Histologically or cytologically proven diagnosis of advanced or metastatic UM or ocular melanoma (arising from ocular melanocytes regardless of intraocular location)
•Patients who have progressed following at least 1 prior immunotherapy treatment for advanced or metastatic UM. For patients who are HLA-A*02:01 positive prior treatment should have included tebentafusp, if available or patients clinically suitable. Patients who have also received prior melphalan hepatic infusion may be included;
•Presence of at least one lesion suitable for biopsy. Biopsies will be mandatory at Screening and C5D1 (see Sections 8.1.3 and 8.6 for more information);
•Presence of at least one measurable lesion as per RECIST v1.
•Any lesion that is biopsied cannot be used as a measurable lesion for the purposes of RECIST v1.1 assessments;
•ECOG performance status of 0 to 1;
•Male or female patients of child-bearing potential must be willing to use highly effective forms of contraception (refer to APPENDIX 7 for details on highly effective methods of contraception and definitions of women of childbearing potential and of fertile men)
•All other relevant medical conditions must be well managed and stable, in the Investigator's opinion, for at least 28 days prior to first dose of roginolisib;
•Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.

排除标准

•Inability to swallow oral medication;
•a). History of a prior Grade 3 or 4 irAE or any grade ocular irAE from prior immunotherapy which did not respond to corticosteroid therapy or resolved with treatment interruptions and returned to at least Grade 1; b). Have not recovered from toxic effect(s) of prior therapy to ≤ Grade 1, other than alopecia or fatigue or neuropathy which must be ≤ Grade 1;
•Presence of symptomatic or untreated CNS metastases or CNS metastases that require doses of corticosteroids within the prior 3 weeks to first dose of roginolisib. Patients with brain metastases are eligible if lesions have been treated with localised therapy and there is no evidence of progressive disease for at least 4 weeks prior to the first dose of IMP;
•Abnormal liver enzymes defined as:
•ALT or AST ≥ 3× upper limit of normal (ULN) (≥ 5× ULN in patients with liver metastases);
•Total bilirubin ≥ 1.5 × ULN are excluded unless direct bilirubin is ≤ ULN. If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin to be eligible (except patients with Gilbert syndrome);
•Any other clinically significant out of range laboratory values;
•Clinically significant cardiac disease or impaired cardiac function which may limit the patient´s participation in the clinical study. These may include unstable angina (i.e., not responsive to medical intervention), myocardial infarct in last 6 months, QTcF prolongation of more than 500 ms;
•Evidence of interstitial lung disease or active, non-infectious pneumonitis, pulmonary fibrosis;
•Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of IMP;
•Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol;
•Malignant disease, other than that being treated in this study (e.g., skin/cutaneous and/or mucosal melanoma). Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to first dose of IMP; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type;
•Any medical condition that would, in the Investigator's or Sponsor's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results;
•Treatment with anti-tumour medications or investigational drugs within 14 days or 5 half-lives (whichever is longer) of administration of first dose of IMP;
•Major surgery within 2 weeks of the first dose of IMP (minimally invasive procedures such as bronchoscopy, tumour biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary);
•Radiotherapy within 4 weeks of the first dose of IMP, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumour mass;
•Pregnant, likely to become pregnant, or lactating women.

研究组 & 干预措施

Arm 1 - Roginolisib 80mg

Experimental

IOA-244: 80 mg (corresponding to 72 mg roginolisib) daily

干预措施: roginolisib (Drug)

Arm 2 - Investigator choice of standard of care

Active Comparator

Investigator´s choice of therapy

干预措施: Investigator choice of standard therapy (Drug)

Arm 3 - Roginolisib 40mg

Experimental

IOA-244: 40 mg (corresponding to 36 mg roginolisib) daily

干预措施: roginolisib (Drug)

结局指标

主要结局

Overall survival

时间窗: Patients will be followed up for overall survival every 12 weeks, for 96 weeks from last patient enrolled, until their death or end of the study

To evaluate clinical efficacy of roginolisib as single agent, against Investigator's choice of therapy by assessment of overall survival (OS)

次要结局

Progression free survival (PFS)(Patients will be followed up for progression free survival every 8 weeks, for 96 weeks from last patient enrolled, until progression of disease, their death or end of the study)
Objective response rate (ORR)(Every 8 weeks whilst on treatment anticipated to be 52 weeks)
Duration of response (DOR)(Every 8 weeks up to 96 weeks from start of treatment)
Time to response(Every 8 weeks whilst on treatment anticipated to be 52 weeks)
Disease control rate (DCR)(Every 8 weeks whilst on treatment anticipated to be 52 weeks)
Clinical benefit rate (CBR)(Measured at Cycle 5 - approximately 16 weeks from start of dosing)
Safety and tolerability(Every 4 weeks whilst on treatment anticipated to be 52 weeks)
Pharmacokinetics (PK)(Every 4 weeks for 52 weeks from start of treatment)
Safety of 40 vs 80 mg of roginolisib(Every 4 weeks whilst on treatment anticipated to be 52 weeks)
Health care utilisation(Every 4 weeks whilst on treatment anticipated to be 52 weeks)
Quality of Life(Every 4 weeks for 52 weeks from start of treatment)

研究者

发起方

iOnctura

申办方类型

Industry

责任方

Sponsor

研究点 (16)

Loading locations...

相似试验

招募中

1 期

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)Relapsed LeukemiaRelapsed CancerRefractory LeukemiaLeukemiaChronic Lymphocytic Leukemia

NCT06644183Jennifer R. Brown, MD, PhD64

进行中（未招募）

2 期

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)Rheumatoid Arthritis

NCT06041269AnaptysBio, Inc.420

已完成

2 期

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaMultiple Myeloma

NCT00639002Incyte Corporation13

终止

2 期

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)MPN (Myeloproliferative Neoplasms)

NCT03123588Incyte Corporation12

已完成

2 期

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)Cutaneous Lupus Erythematosus

NCT03134222Gilead Sciences47